Liver Chemistries in COVID-19 Patients with Survival or Death: A Meta-Analysis

Short title: Liver Chemistries in COVID-19

Qing-Qing Xing1*, Xuan Dong2*, Yan-Dan Ren3*, Wei-Ming Chen2, Dan-Yi Zeng2, Yan-Yan Cai1, Mei-Zhu Hong4†, and Jin-Shui Pan1,2†

1Liver Research Center, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China;
2School of Medicine, Xiamen University, Xiamen, Fujian, China;
3Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China;
4Department of Traditional Chinese Medicine, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China

*These authors contributed equally to this work.

E-mails:
Qing-Qing Xing 582398903@qq.com
Xuan Dong 362485659@qq.com
Yan-Dan Ren 916659998@qq.com
Wei-Ming Chen 345173327@qq.com
Dan-Yi Zeng 1184359451@qq.com
Liver Chemistries in Patients with COVID-19

Yan-Yan Cai 474349346@qq.com
Mei-Zhu Hong 546777397@qq.com
Jin-Shui Pan j.s.pan76@gmail.com

†Correspondence:
Jin-Shui Pan, MD, PhD
Liver Research Center
the First Affiliated Hospital of Fujian Medical University
No. 20 Chazhong Road,
Fuzhou 350001, Fujian, China.
E-mail: j.s.pan76@gmail.com

Mei-Zhu Hong, MD
Department of Traditional Chinese Medicine
Zhongshan Hospital Affiliated to Xiamen University
201 Hu-Bin Nan Road
Xiamen, Fujian 361004, China
E-mail: 546777397@qq.com
Tel: +86-592-229-2015

Word count: 2750
Word count of abstract: 237
Number of tables: 1; Number of figures: 5
Number of supplementary figures: 5
Liver Chemistries in Patients with COVID-19

ABSTRACT

Background and Aims: Although abnormal liver chemistries are linked to higher risk of death related to coronavirus disease (COVID-19), liver manifestations may be diverse and even confused. Thus, we performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19 patients with death or survival.

Methods: We searched PubMed, Google Scholar, medRxiv, bioRxiv, Cochrane Library, Embase, and three Chinese electronic databases through April 22, 2020. We analyzed pooled data on liver chemistries stratified by the main clinical outcome of COVID-19 using a fixed or random-effects model.

Results: In the meta-analysis of 18 studies, which included a total of 2,862 patients, the pooled mean alanine aminotransferase (ALT) was 30.9 IU/L in the COVID-19 patients with death and 26.3 IU/L in the COVID-19 patients discharged alive (p < 0.0001). The pooled mean aspartate aminotransferase (AST) level was 45.3 IU/L in the COVID-19 patients with death while 30.1 IU/L in the patients discharged alive (p < 0.0001). Compared with the discharged alive cases, the dead cases tended to have lower albumin levels but longer prothrombin time, and international standardized ratio.

Conclusions: In this meta-analysis, according to the main clinical outcome of COVID-19, we comprehensively described three patterns of liver impairment related to COVID-19, hepatocellular injury, cholestasis, and hepatocellular disfunction. Patients died from COVID-19 tend to have different liver chemistries from those are discharged alive. Close monitoring of liver chemistries provides an early warning against COVID-19 related death.
Liver Chemistries in Patients with COVID-19

74  **KEYWORDS:** PRISMA, COVID-19, SARS-CoV-2, mortality, Meta-analysis
Lay Summary

Abnormal liver chemistries are linked to higher risk of death related to coronavirus disease (COVID-19). We performed a meta-analysis of 18 studies that included a total of 2,862 patients with COVID-19. We noted that patients died from COVID-19 tend to have different liver chemistries from those are discharged alive and close monitoring of liver chemistries provides early warning against COVID-19 related death.
INTRODUCTION

Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which is non-segmented positive-sense RNA viruses with envelope that belongs to the family Coronaviridae. Coronavirus widely distributes in humans and other mammals. In the past twenty years, coronavirus has caused several localized epidemics and even global pandemics, such as severe acute respiratory syndrome (SARS), Middle East Respiratory Syndrome (MERS), and the ongoing COVID-19. Worldwide, the spread and upward trend of COVID-19 have accelerated dramatically. According to the situation report released by the World Health Organization (WHO), as of April 25, 2020, 2,719,897 coronavirus disease (COVID-19) cases were confirmed globally with a fatality rate of 6.9% [1]. In response to the emerging threat, the WHO has declared a Public Health Emergency of International Concern on January 30, 2020, and further labeled as a pandemic on March 11, 2020. Compared with SARS and MERS, the case fatality rate of COVID-19 is relatively lower, which are 6.8% and 60% in SARS and MERS, respectively [2, 3]. Although the case fatality rate of COVID-19 is lower than those of SARS and MERS, the reproductive numbers of COVID-19 is even higher than of SARS [4]. Due to the huge number of confirmed cases, COVID-19 causes much more deaths than SARS or MERS.

Apart from lung injury, COVID-19 also leads to myocardial dysfunction, liver impairment, and acute kidney injury [5, 6]. Chronic hypertension and other cardiovascular comorbidities are frequent risk factors for COVID-19 related death [6, 7]. Other conditions can also contribute to death. According to the observation by Wu et al [7], coagulation dysfunction is linked to likelihood of death. Moreover, univariable logistic regression reveals the association between alanine
Liver Chemistries in Patients with COVID-19

aminotransferase (ALT), and total bilirubin (TBIL) and higher risk of death related to COVID-19 [8]. Another study by Fu et al [9] has shown the potential relationship between hypoproteinemia, cholestasis and higher fatality rate of the patients with COVID-19. Our meta-analysis also reveals the different patterns of abnormal liver chemistries between patients with severe and non-severe COVID-19 [10].

According to the clinical guideline proposed by American College of Gastroenterology, liver chemistries can be classified into three groups, in other words, hepatocellular injury-related indexes, including ALT and aspartate aminotransferase (AST); cholestatic injury-related indexes, comprised of alkaline phosphatase (AKP) and \( \gamma \)-glutamyltransferase (GGT); and hepatocellular function-related indexes such as albumin (ALB) level and prothrombin time (PT) [11]. In clinical practice, TBIL and direct bilirubin (DBIL), globulin (GLB) levels, and international standardized ratio (INR) are also assessed. Clinical manifestations of COVID-19 are diverse and even confusing. Comprehensive evaluation of the abnormalities of liver chemistries in patients with COVID-19 are rather few. Hence, the aim of this study was to provide a comprehensive view of liver test parameters in the COVID-19 patients with death or survival.
METHODS

Studies selection

The following databases were searched from December 1, 2019 to April 22, 2020, including PubMed, Google Scholar, medRxiv, bioRxiv, Embase, Cochrane Library, and three Chinese electronic databases (Chinese National Knowledge Infrastructure CQVIP, and Wanfang Data). “COVID-19”, “Coronavirus”, “SARS-CoV-2”, “2019-nCoV-2” or novel coronavirus were set as keywords for searching. The PRISMA guideline was implemented in the retrieval of potential studies[12]. Details of searching PubMed were listed in the Supplementary file. Endnote X9.3 (Thompson and Reuters, Philadelphia, Pennsylvania) was employed to manage the retrieved articles. Duplicated articles were removed.

Selection criteria

Two authors (XD and QQX) independently determined the eligibility of the potential studies. Dissonance was arbitrated by the third author (JSP). The inclusion criteria were listed as the following: (1) study population: adult COVID-19 patients with death or survival; (2) study design: case report, case series, retrospective cohort study, prospective cohort study, randomized controlled trial, and case-control study; and (3) language: studies published in English or Chinese. The exclusion criteria were as follows: (1) pregnant women or pediatric patients; (2) patients who lack of nucleic acid data or serology evidence of SARS-CoV2 infection; (3) asymptomatic patients with SARS-CoV2 infection; (3) study design: commentary, editorial, review article, meta-analysis; (4) results: Studies that only reported the percentages of the indexes related to liver chemistries rather than the mean or average values of the corresponding indices, and studies that included only one arm (for example, only data
Liver Chemistries in Patients with COVID-19

of dead cases were reported without data from survival cases, or only data of survival cases were reported without data from dead cases) were also excluded.

Data extraction

For the eligible articles, the following items: first author, study location, sample size, patient age and sex, and liver chemistry-related indexes such as TBIL, DBIL, ALT, AST, GGT, AKP, and ALB levels, were recorded. The main outcome (dead or survival) of COVID-19 was also recorded.

Data analysis

R statistical platform (version 3.2.3, R Foundation for Statistical Computing) was used for statistical analysis. Continuous variables submitted to normal distribution were expressed as mean ± SD, while median (interquartile range [IQR]) was employed for the expression of those variables conformed to a skewed distribution. The method developed by Luo et al [13] was employed to estimate the sample mean and SD for the continuous outcomes from the studies that provided summary data of median, minimum, and maximum values. Related online tool is provided at http://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html. The 95% confidence interval (CI) was presented in Forest plot. Heterogeneity among studies was detected by the Cochran Q test, with a p value of <0.10 indicating significant heterogeneity. The proportion of total variation among the studies, from which heterogeneity was derived, was measured by the $I^2$ statistics. $I^2$ values of <25%, 25–75%, and >75% represent low, moderate, and high heterogeneity, respectively [14]. Funnel plot was used to evaluated publication bias. A subgroup analysis was performed according to the main clinical outcome—death or survival.
Liver Chemistries in Patients with COVID-19

RESULTS

Characteristics of the studies included in the meta-analysis

Selection process of potential studies was depicted in Figure 1. From the identified 1,841 studies, 18 studies were included in the meta-analysis. The characteristics of the enrolled studies are listed in Table 1 [6-8, 15-29]. Information including the study location, sample size, patient age and sex, clinical outcome, TBIL, DBIL, ALT, AST, GGT, AKP, ALB, GLB, PT, and INR was recorded. The mean ages of COVID-19 patients discharged alive and died were 56.4 and 68.7 years, respectively (Supplementary Figure 1). In the enrolled studies, male patients accounted for 55.3%. Among the studies that reported death cases, death case accounted for 31.6% (range, 11.7–61.5%) of the cases.

Hepatocellular injury-related abnormalities in liver chemistries

In the enrolled studies, 14 reported assays of ALT or AST in a total of 2,365 patients with COVID-19. All of these studies were from China. In the 18 enrolled studies, 14 (77.8%) were from Hubei Province, where Wuhan is located. The pooled mean ALT level was 30.9 IU/L in the COVID-19 patients with death and 26.3 IU/L in the COVID-19 patients discharged alive (95% CI: −6.1 to −2.9, p < 0.0001; Figure 2A), with moderate heterogeneity among the studies ($I^2 = 42\%$, $p = 0.05$). Similarly, the pooled mean AST level was 45.3 IU/L in the COVID-19 patients with death and 30.1 IU/L in the patients discharged alive (95% CI: −18.3 to −8.6, p < 0.0001; Figure 2B). Significant heterogeneity was observed for the AST levels among the studies ($I^2 = 74\%$, $p < 0.01$), which was significantly higher than that of the ALT levels ($I^2 = 42\%$, $p = 0.05$). Potential publication bias existed in ALT/AST was evaluated using a funnel plot (Supplementary Figure 2). In the patients with COVID-19, the mean AST level
Liver Chemistries in Patients with COVID-19

tended to be higher than the mean ALT level in both the died and discharged alive groups. Moreover, the gap between the AST and ALT levels (45.3 and 29.8 IU/L, respectively) was even more significant in the group discharged alive (Figure 3).

Evaluation of potential publication bias was also presented in Supplementary Figure 3.

**Cholestasis-related abnormalities in liver chemistries**

We cannot enroll enough studies to analysis cholestasis-related indexes such as AKP, and DBIL levels, since rather few studies focused on these indexes. Of the enrolled studies for the meta-analysis, 3 reported GGT assays and 11 studies reported TBIL measurements. The pooled mean GGT level was 46.3 IU/L in the group with death and 34.3 IU/L in the group discharged alive (Figure 4A). The pooled mean TBIL level in the group with death was slightly higher than that in the group discharged alive. However, the mean TBIL levels remained within the normal range in both groups (Figure 4B). For the TBIL levels, moderate heterogeneity was observed among the studies ($I^2 = 36\%, p = 0.11$). Funnel plot for the TBIL levels was shown in Supplementary Figure 4.

**Hepatocellular function-related abnormalities in liver chemistries**

Eleven studies compared the mean ALB levels according to the main clinical outcome of COVID-19, between 683 and 1,383 died and discharged alive cases, respectively (Figure 5A). High heterogeneity was observed among the studies ($I^2 = 80\%, p < 0.01$). The mean ALB level in the patients with death was significantly lower than that in the patients discharged alive. There were significant differences in the coagulation-related indexes such as PT and INR between the two groups. The patients in the group with dead had longer PT or higher INR (Figure 5B, 5C). Evaluation of publication bias related to ALB level and PT was shown in Supplementary Figure 5.
DISCUSSION

In this meta-analysis, 18 studies, all from China, consisted a total of 3,025 patients with COVID-19 were enrolled. Three patterns of liver impairment, namely hepatocellular injury, cholestasis, and hepatocellular dysfunction, can develop in proportion of patients with COVID-19, especially in the patients who eventually died. Briefly, the patients who died of COVID-19 tended to have higher baseline ALT/AST, TBIL, INR, and prolonged PT while lower ALB than the survival cases. The patients with COVID-19 usually had higher AST levels than ALT levels, especially in the non-survival. There was a tendency of the dead cases to arise in the elderly.

Should be noted, the pooled percentage of death cases accounted up 31.6%, which was calculated according to the proportion of death cases in each enrolled selected study. It does not intend to mean that the percentage of death cases in the whole population reaches that high. Several reasons that may lead to the higher percentages of death cases in the enrolled study than those in the whole population. First, since the patients in the enrolled studies are all hospitalized or even critically ill patients, it sounds reasonable that the percentage of death case is higher than that in the whole population. Second, the composition difference exists in the enrolled studies caused by the selection of the reporter. Similar to our previous study, most studies focus on ALT/AST rather than cholestasis-related indexes such as AKP and GGT levels [10]. In other words, the actual prevalence of abnormal liver chemistries could be underestimated in the studies reporting clinical features of COVID-19. Thus, the role of liver chemistries was compromised in disease monitoring and early warning against potential death cases.

The possible mechanisms of COVID-19 related liver injury include the direct damage of SARS-CoV-2 to the liver, and the secondary liver injury caused by stress and
Liver Chemistries in Patients with COVID-19

systemic inflammatory response, liver ischemia or hypoxia, exacerbation of underlying liver disease, drug-induced liver injury [30]. In addition, for HBsAg positive patients, the following events can also lead to liver injury: sudden cessation of ongoing antiviral treatment in the patients with chronic hepatitis B patients, which may result in sharp deterioration of liver chemistries or acute-on-chronic liver failure; application of high dose corticosteroids without antiviral therapy, which may bring about activate replication of HBV. Clinically, secondary liver injury is far more frequent than direct liver injury [31].

The most frequent complications of deceased patients caused by COVID-19 are the following: acute respiratory distress syndrome, sepsis, acute cardiac injury, type I respiratory failure, followed by heart failure [6]. The percentage of developing acute liver injury is 9% in deceased patients whereas is only 2% in recovered patients [6]. Investigation by Deng et al [17] also indicated the high frequency of developing acute respiratory distress syndrome (89.9%), acute cardiac injury (59.6%), acute kidney injury (18.3%) in the patients with death. Sepsis or liver ischemia caused by acute respiratory distress syndrome or heart failure can further bring about abnormalities of liver chemistries or even disordered coagulopathy.

On the whole, the alteration of liver chemistries between the survival group and non-survival group is similar to that between the severe group and the non-severe group, shown in our recent study [10], although there are some differences. Similar to the age difference between severe and non-severe group, our analysis also found that the average age of the non-survival group was significantly higher than that of survival group. The average ALT and AST in the dead group were also higher than those in the non-survival group. Moreover, both in the non-survival group and survival group, the average AST was higher than ALT, which was also similar to our previous study.
Liver Chemistries in Patients with COVID-19

[10]. GGT in the non-survival group was higher than that in the survival group. However, there was no statistical significance. This may be due to the under-reported on GGT. TBIL in the non-survival group was also higher than that in the survival group whereas the average values of TBIL in both groups were all within the normal range. ALB in the non-survival group was significantly lower than that in the survival group, which was in accordance with our study between severe and non-severe group [10]. In the non-survival group, PT and INR were significantly longer than those in the survival group, which was even more remarkable than the difference we previously observed between the severe group and non-severe group. This suggests that the coagulation function of non-survival group is significantly worse than that of survival group. Since almost all of coagulation factors are synthesized in the liver, it can be speculative that the hepatocellular disfunction in the non-survival group was exacerbated under the influence of multiple factors such as hypoxemia, inflammation storm, infection. In fact, severe sepsis is almost invariably associated with systemic activation of coagulation [32, 33].

In this study, we found that the abnormalities of liver chemistries in the non-survival group was worse than that in the survival group, which suggested that we should be alert to the risk of death for the patients with significantly abnormal liver chemistries on admission. Dramatical hypoalbuminemia usually developed in the non-survival group. Thus, solid nutrition support is necessary. In addition, if there is obvious coagulation dysfunction on admission, we should be aware of the risk of severe case or even death. It is necessary to correct the coagulation disfunction as early as possible to prevent the further deterioration of the condition. Several substantial merits can be seen in this study. First, the literatures focused on COVID-19 related abnormal liver chemistries are rapidly evolving and sometimes
Liver Chemistries in Patients with COVID-19

confusing. This meta-analysis comprehensively summarized the related literatures according to the main clinical outcome—death or survival. The extensive coverage of over 2,800 studies allowed a more precise evaluation of the abnormalities of liver chemistries in the patients with COVID-19. Our analysis revealed that abnormal liver chemistries were associated with a worse clinical outcome and even death, which highlights the importance of a more extensive monitoring on liver chemistries for the purposes of both diagnosis and prognosis. Second, three patterns of liver impairment, namely hepatocellular injury, cholestasis, and hepatocellular dysfunction were all extensively covered in this analysis. However, cholestasis-related indices such as AKP and GGT tended to be inadvertently ignored, which is even more significant than that in our previous study [10]. We also compared hepatocellular dysfunction between the survival and non-survival cases. The alarmingly high prevalence of hypoalbuminemia and coagulation dysfunction in the non-survival group requires vigilance. Third, we also covered the eligible studies preprinted in medRxiv, which ensured that our meta-analysis has a clear leading position. However, our study has a few limitations. As mentioned earlier, cholestasis-related indices were remarkably under-reported, which hindered us from getting more precise pooled data. Second, all the enrolled studies came from mainland China, which restricted a more precise estimation of abnormal liver chemistries in the context of diverse other ethnics. However, this conversely helps to abate the heterogeneity caused by the physiological differences.
CONCLUSION

In this analysis, we comprehensively described three patterns of liver impairment related to COVID-19 including hepatocellular injury, cholestasis, and hepatocellular dysfunction, according to the main clinical outcome of COVID-19. Patients with abnormal liver chemistries are at higher risk of worse outcome. Close monitoring on liver chemistries, especially coagulation-related indexes, is beneficial to early warning against worse outcome.
Acknowledgments

Financial support: This work was supported by the National Natural Science Foundation of China No. 81871645 (JSP). The funding source did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Guarantor of the article: Professor Jin-Shui Pan

Specific author contributions: JSP and MZH were involved with the study conceptualization and design; analysis and interpretation of data; drafting of the manuscript; and approval of the final version of the manuscript; XD, DYZ, YYC, WMC, QQX, and YDR were involved in data retrieval.

Potential competing interests: None.
<table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Number</th>
<th>Age [(mean±SD, or median (IQR)]</th>
<th>Male, number (%)</th>
<th>Died, number (%)</th>
<th>TBIL [(mean±SD, or median (IQR)]</th>
<th>DBIL [(mean±SD, or median (IQR)]</th>
<th>ALT [(mean±SD, or median (IQR)]</th>
<th>AST [(mean±SD, or median (IQR)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luo X[21]</td>
<td>Hubei</td>
<td>403</td>
<td>56.0 (39.0–68.0)</td>
<td>193 (47.9)</td>
<td>100 (40.3)</td>
<td>12.8 (10.0–17.5)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Chen T[15]</td>
<td>Hubei</td>
<td>55</td>
<td>74.0 (65.0–91.0)</td>
<td>34 (61.8)</td>
<td>19 (34.5)</td>
<td>NA</td>
<td>NA</td>
<td>41.3 (8.0–279.0)</td>
<td>63.1 (18.0–209.0)</td>
</tr>
<tr>
<td>Chen T[6]</td>
<td>Hubei</td>
<td>274</td>
<td>62.0 (44.0–70.0)</td>
<td>171 (62.4)</td>
<td>113 (41.2)</td>
<td>9.6 (6.7–13.5)</td>
<td>NA</td>
<td>23.0 (15.0–38.0)</td>
<td>30.0 (22.0–46.0)</td>
</tr>
<tr>
<td>Deng Y[17]</td>
<td>Hubei</td>
<td>225</td>
<td>NA</td>
<td>124 (55.1)</td>
<td>109 (48.4)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Ruan Q[22]</td>
<td>Hubei</td>
<td>150</td>
<td>NA</td>
<td>NA</td>
<td>68 (45.3)</td>
<td>15.2±9.1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Du R[18]</td>
<td>Hubei</td>
<td>179</td>
<td>57.6±13.7</td>
<td>97 (54.2)</td>
<td>21 (11.7)</td>
<td>8.9 (6.6–12.5)</td>
<td>2.5 (1.8–3.9)</td>
<td>22.0 (15.0–40.0)</td>
<td>30.0 (19.0–43.0)</td>
</tr>
<tr>
<td>Wang L[24]</td>
<td>Hubei</td>
<td>339</td>
<td>69.0 (65.0–76.0)</td>
<td>166 (49.0)</td>
<td>65 (19.2)</td>
<td>NA</td>
<td>NA</td>
<td>27.0 (17.0–44.0)</td>
<td>32.0 (23.0–46.0)</td>
</tr>
<tr>
<td>Zhou F[29]</td>
<td>Hubei</td>
<td>191</td>
<td>56.0 (46.0–67.0)</td>
<td>119 (62.3)</td>
<td>54 (28.3)</td>
<td>NA</td>
<td>NA</td>
<td>30.0 (17.0–46.0)</td>
<td>NA</td>
</tr>
<tr>
<td>Li K[20]</td>
<td>Hubei</td>
<td>102</td>
<td>57.0 (45.0–70.0)</td>
<td>59 (57.8)</td>
<td>15 (14.7)</td>
<td>8.5 (6.6–11.6)</td>
<td>NA</td>
<td>23.0 (14.0–34.3)</td>
<td>26.0 (19.0–41.8)</td>
</tr>
<tr>
<td>Wang Y[25]</td>
<td>Jiangsu</td>
<td>344</td>
<td>64.0 (52.0–72.0)</td>
<td>179 (52.0)</td>
<td>133 (38.7)</td>
<td>10.2 (7.3–14.2)</td>
<td>NA</td>
<td>24.0 (15.0–38.0)</td>
<td>31.0 (22.0–47.0)</td>
</tr>
<tr>
<td>Fu L[8]</td>
<td>Anhui</td>
<td>200</td>
<td>60.0 (48.0–66.0)</td>
<td>99 (49.5)</td>
<td>34 (17.0)</td>
<td>11.4 (9.0–15.6)</td>
<td>3.3 (2.3–5.0)</td>
<td>23.5 (16.0–42.0)</td>
<td>35.0 (23.4–56.8)</td>
</tr>
<tr>
<td>Zhang F[28]</td>
<td>Hubei</td>
<td>48</td>
<td>70.6±13.4</td>
<td>33 (68.8)</td>
<td>17 (35.4)</td>
<td>NA</td>
<td>NA</td>
<td>21.0 (12.5–34.0)</td>
<td>32.0 (22.0–51.8)</td>
</tr>
<tr>
<td>Yang X[27]</td>
<td>Hubei</td>
<td>52</td>
<td>59.7±13.3</td>
<td>35 (67.3)</td>
<td>32 (61.5)</td>
<td>17.0±9.9</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
### Liver Chemistries in Patients with COVID-19

<table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Number</th>
<th>GGT [(mean±SD, or median (IQR)]</th>
<th>AKP [(mean±SD, or median (IQR)]</th>
<th>ALB [(mean±SD, or median (IQR)]</th>
<th>GLB [(mean±SD, or median (IQR)]</th>
<th>PT [(mean±SD, or median (IQR)]</th>
<th>INR [(mean±SD, or median (IQR)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wu C[7]</td>
<td>Hubei</td>
<td>84</td>
<td>58.5 (50.0–69.0)</td>
<td>60 (71.4)</td>
<td>44 (52.4)</td>
<td>12.9 (9.5–17.1)</td>
<td>NA</td>
<td>35.0 (21.5–52.5)</td>
</tr>
<tr>
<td>Fu Y[19]</td>
<td>Chongqing</td>
<td>85</td>
<td>64.0 (54.5–70.0)</td>
<td>49 (57.6)</td>
<td>14 (16.5)</td>
<td>NA</td>
<td>NA</td>
<td>29.0 (20.0–55.0)</td>
</tr>
<tr>
<td>Hu C[16]</td>
<td>Hubei</td>
<td>183</td>
<td>NA</td>
<td>107 (58.5)</td>
<td>68 (37.2)</td>
<td>11.3±5.6</td>
<td>NA</td>
<td>28.1±20.0</td>
</tr>
<tr>
<td>Xu Y[26]</td>
<td>Shanghai</td>
<td>10</td>
<td>NA</td>
<td>6 (60.0)</td>
<td>2 (20.0)</td>
<td>NA</td>
<td>NA</td>
<td>24.0 (20.0–39.0)</td>
</tr>
<tr>
<td>Shi Q[23]</td>
<td>Hubei</td>
<td>101</td>
<td>71.0 (59.0–80.0)</td>
<td>60 (59.4)</td>
<td>48 (47.5)</td>
<td>12.0 (8.4–19.1)</td>
<td>NA</td>
<td>25.0 (18.0–48.3)</td>
</tr>
<tr>
<td>Luo X[21]</td>
<td>Hubei</td>
<td>403</td>
<td>NA</td>
<td>NA</td>
<td>37.4 (33.3–40.8)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Chen T[15]</td>
<td>Hubei</td>
<td>55</td>
<td>NA</td>
<td>NA</td>
<td>33.3 (25.0–43.0)</td>
<td>30.0 (20.0–48.0)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Chen T[6]</td>
<td>Hubei</td>
<td>274</td>
<td>33.0 (21.0–51.0)</td>
<td>68.0 (55.0–87.0)</td>
<td>33.9 (30.3–37.6)</td>
<td>NA</td>
<td>14.3 (13.4–15.4)</td>
<td>1.1 (1.0–1.2)</td>
</tr>
<tr>
<td>Deng Y[17]</td>
<td>Hubei</td>
<td>225</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Ruan Q[22]</td>
<td>Hubei</td>
<td>150</td>
<td>NA</td>
<td>NA</td>
<td>30.9±4.3</td>
<td>NA</td>
<td>11.1 (10.1–12.4)</td>
<td>NA</td>
</tr>
<tr>
<td>Du R[18]</td>
<td>Hubei</td>
<td>179</td>
<td>29.0 (17.0–52.5)</td>
<td>NA</td>
<td>33.2 (30.7–36.4)</td>
<td>NA</td>
<td>13.7 (12.4–15.4)</td>
<td>NA</td>
</tr>
<tr>
<td>Wang L[24]</td>
<td>Hubei</td>
<td>339</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>12.1 (11.6–12.7)</td>
<td>NA</td>
</tr>
<tr>
<td>Zhou F[29]</td>
<td>Hubei</td>
<td>191</td>
<td>NA</td>
<td>NA</td>
<td>32.3.0 (29.1–35.8)</td>
<td>NA</td>
<td>11.6 (10.6–13.0)</td>
<td>NA</td>
</tr>
<tr>
<td>Name</td>
<td>Province</td>
<td>Patient ID</td>
<td>Age</td>
<td>Sex</td>
<td>Gender</td>
<td>ALT (U/L)</td>
<td>AST (U/L)</td>
<td>ALB (g/L)</td>
</tr>
<tr>
<td>-------</td>
<td>----------</td>
<td>------------</td>
<td>------</td>
<td>------</td>
<td>--------</td>
<td>-----------</td>
<td>----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Li K</td>
<td>Hubei</td>
<td>102</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>34.8 (31.7–39.5)</td>
<td>NA</td>
<td>14.2 (13.7–14.8)</td>
</tr>
<tr>
<td>Wang Y</td>
<td>Jiangsu</td>
<td>344</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>34.0 (30.0–37.0)</td>
<td>NA</td>
<td>14.3 (13.5–15.4)</td>
</tr>
<tr>
<td>Fu L</td>
<td>Anhui</td>
<td>200</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Zhang F</td>
<td>Hubei</td>
<td>48</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Yang X</td>
<td>Hubei</td>
<td>52</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>30.4 (27.2–33.4)</td>
<td>31.6 (29.4–35.1)</td>
<td>11.7 (11.1–12.5)</td>
</tr>
<tr>
<td>Wu C</td>
<td>Hubei</td>
<td>84</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>33.9 ±5.6</td>
<td>NA</td>
<td>14.5 ±1.9</td>
</tr>
<tr>
<td>Fu Y</td>
<td>Chongqing</td>
<td>85</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hu C</td>
<td>Hubei</td>
<td>183</td>
<td>44.1±41.7</td>
<td>73.2±30.3</td>
<td>33.9±5.6</td>
<td>NA</td>
<td>12.3 (11.7–13.1)</td>
<td>NA</td>
</tr>
<tr>
<td>Xu Y</td>
<td>Shanghai</td>
<td>10</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>33.0 (30.3–36.4)</td>
<td>NA</td>
<td>12.8 (12.0–14.0)</td>
</tr>
</tbody>
</table>

Abbreviations: SD, standard deviation; IQR, interquartile range; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-Glutamyltransferase; AKP, alkaline phosphatase; ALB, albumin; GLB, globulin; PT, prothrombin time; INR, international standardized ratio; NA, not available.
Liver Chemistries in Patients with COVID-19

FIGURE LEGENDS

Figure 1. Study selection flow diagram

If all the liver chemistry indexes were not reported, they were excluded from the meta-analysis. The studies that included only one arm (for example, only data of dead cases were reported without data from survival cases, or only data of survival cases were reported without data from dead cases) were also excluded.
Liver Chemistries in Patients with COVID-19

Figure 2. Forest plot of the association between serum ALT/AST level and the main clinical outcomes—died or discharged alive.

Pooled levels of (A) ALT and (B) AST in the patients with COVID-19 stratified by clinical outcome.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Liver Chemistries in Patients with COVID-19

Figure 3. Forest plot for the comparison of ALT and AST levels in the patients with COVID-19 stratified by clinical outcome

A, Forest plot for the comparison of ALT and AST levels in the group discharged alive. B, Forest plot for the comparison of ALT and AST levels in the group with death.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Liver Chemistries in Patients with COVID-19

Figure 4. Forest plot for the association of the cholestasis-related indexes and clinical outcome.

Pooled levels of (A) GGT, and (B) TBIL in the patients with COVID-19.

Abbreviations: GGT, γ-Glutamyltransferase; TBIL, total bilirubin.
Liver Chemistries in Patients with COVID-19

Figure 5. Forest plot for the association of the synthetic function-related indexes and clinical outcome

Pooled (A) ALB levels, (B) PTs, and (C) INRs in the patients with COVID-19.

Abbreviations: ALB, albumin; PT, prothrombin time; INR, international standardized ratio.
REFERENCES


Liver Chemistries in Patients with COVID-19


Liver Chemistries in Patients with COVID-19


Liver Chemistries in Patients with COVID-19


